Boas F Edward, Brody Lynn A, Erinjeri Joseph P, Yarmohammadi Hooman, Shady Waleed, Kishore Sirish, Sofocleous Constantinos T
1 Division of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065.
AJR Am J Roentgenol. 2016 Sep;207(3):671-5. doi: 10.2214/AJR.15.15767. Epub 2016 Jun 1.
Colorectal liver metastases (CLM) have a variable response to radioembolization. This may be due at least partly to differences in tumor arterial perfusion. The present study examines whether quantitative measurements of enhancement on preprocedure triphasic CT can be used to predict the response of CLM to radioembolization.
We retrospectively reviewed patients with CLM treated with radioembolization who underwent pretreatment PET/CT and triphasic CT examinations and posttreatment PET/CT examinations. A total of 31 consecutive patients with 60 target tumors were included in the present study. For each tumor, we calculated the hepatic artery coefficient (HAC), portal vein coefficient (PVC), and arterial enhancement fraction (AEF) based on enhancement measurements on pretreatment triphasic CT. HAC and PVC are estimates of the hepatic artery and portal vein blood supply. AEF, which is the arterial phase enhancement divided by the portal phase enhancement, provides an estimate of the hepatic artery blood supply as a fraction of the total blood supply. For each tumor, the metabolic response to radioembolization was based on findings from the initial follow-up PET/CT scan obtained at 4-8 weeks after treatment.
A total of 55% of CLM had a complete or partial metabolic response. Arterial phase enhancement, the HAC, and the PVC did not predict which tumors responded to radioembolization. However, the AEF was statistically significantly greater in tumors with a complete or partial metabolic response than in tumors with no metabolic response (i.e., those with stable disease or disease progression) (p = 0.038). An AEF of less than 0.4 was associated with a 40% response rate, whereas an AEF greater than 0.75 was associated with a 78% response rate.
Response to radioembolization can be predicted using the AEF calculated from the preprocedure triphasic CT.
结直肠癌肝转移(CLM)对放射性栓塞的反应存在差异。这可能至少部分归因于肿瘤动脉灌注的不同。本研究旨在探讨术前三相CT增强的定量测量是否可用于预测CLM对放射性栓塞的反应。
我们回顾性分析了接受放射性栓塞治疗的CLM患者,这些患者在治疗前接受了PET/CT和三相CT检查,治疗后接受了PET/CT检查。本研究共纳入31例连续患者,共60个靶肿瘤。对于每个肿瘤,我们根据术前三相CT的增强测量值计算肝动脉系数(HAC)、门静脉系数(PVC)和动脉增强分数(AEF)。HAC和PVC是肝动脉和门静脉血供的估计值。AEF是动脉期增强除以门静脉期增强,可作为肝动脉血供占总血供比例的估计值。对于每个肿瘤,对放射性栓塞的代谢反应基于治疗后4-8周进行的首次随访PET/CT扫描结果。
共有55%的CLM出现完全或部分代谢反应。动脉期增强、HAC和PVC均无法预测哪些肿瘤对放射性栓塞有反应。然而,完全或部分代谢反应的肿瘤的AEF在统计学上显著高于无代谢反应(即疾病稳定或进展)的肿瘤(p = 0.038)。AEF小于0.4与40%的反应率相关,而AEF大于0.75与78%的反应率相关。
术前三相CT计算的AEF可用于预测对放射性栓塞的反应。